SCHEMBL2818384

SCHEMBL2818384

O=C(O)C1CC(NCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)CN1Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BCHE P06276 2/20 0.48
ACHE P22303 2/20 0.48
BACE1 P56817 2/20 0.48
CCR2 P41597 2/20 0.47
TEAD1 P28347 2/20 0.44
SIGMAR1 Q99720 1/20 0.43
S1PR1 P21453 2/20 0.43
S1PR5 Q9H228 2/20 0.43
CARM1 Q86X55 1/20 0.43
PRMT6 Q96LA8 1/20 0.43
GRK5 P34947 1/20 0.43
CDK8 P49336 1/20 0.43
TACR1 P25103 7/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
TACR2 P21452 1/20 0.42
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
PDGFRA P16234 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2824751 0.91 CCR2 (0.49) BCHEACHEBACE1CCR2TEAD1
SCHEMBL2817642 0.86 ACHE (0.52) BCHEACHEBACE1MEN1KMT2A
SCHEMBL3638635 0.85 SIGMAR1 (0.48) BCHEACHEBACE1CCR2TEAD1
SCHEMBL2817216 0.85 SIGMAR1 (0.48) BCHEACHEBACE1CCR2TEAD1
SCHEMBL2819358 0.83 TACR1 (0.51) BCHEACHEBACE1CCR2TEAD1
SCHEMBL2818101 0.82 CHRM4 (0.52) TEAD1SIGMAR1KMT2ADRD2
SCHEMBL3638063 0.82 CHRM4 (0.52) TEAD1SIGMAR1KMT2ADRD2
SCHEMBL2818348 0.80 CHRM4 (0.44) BCHETEAD1TACR1MEN1KMT2A
SCHEMBL2820849 0.80 CHRM4 (0.47) BCHEACHEBACE1TEAD1TACR1
SCHEMBL2822830 0.76 NPFFR1 (0.53) BCHEACHEBACE1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155672-B1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-10-27 EP disclosed
EP-2155672-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-02-24 EP disclosed
US-7528136-B2 for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD); 2-{4-[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
WO-2008148689-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-12-11 WO disclosed
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS SLC6A3, OPRL1, OPRK1 BCHE 2225/4885ACHE 548/4885BACE1 1862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.